Therapeutic utilities of fibroblast growth factor 19

Expert Opinion on Therapeutic Targets

Volumn 15, Issue 11, 2011, Pages 1307-1316

  Wu, Xinle ^a   Li, Yang ^a  

^a AMGEN INC   (United States)

Author keywords

Diabetes; FGF19; FGF21; FGFR1; FGFR4; Fibroblast growth factor; Metabolic disorders; Obesity

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE; BILE ACID; CARNITINE PALMITOYLTRANSFERASE; CELL NUCLEUS RECEPTOR; CHOLESTEROL; CHOLESTEROL 7ALPHA MONOOXYGENASE; CORTICOSTERONE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; FARNSOID X RECEPTOR; FIBROBLAST GROWTH FACTOR 19; GLITAZONE DERIVATIVE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCOSE; GLYCOGEN SYNTHASE KINASE 3ALPHA; GLYCOGEN SYNTHASE KINASE 3BETA; INITIATION FACTOR 4B; INITIATION FACTOR 4E; INSULIN; LIPID; RECOMBINANT FIBROBLAST GROWTH FACTOR 15; RECOMBINANT FIBROBLAST GROWTH FACTOR 19; RECOMBINANT GROWTH FACTOR; SULFONYLUREA; THYROID HORMONE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BILE ACID METABOLISM; BILE ACID SYNTHESIS; BINDING AFFINITY; BLOOD GLUCOSE MONITORING; BODY WEIGHT; CELL PROLIFERATION; CHOLELITHIASIS; CHOLESTEROL BLOOD LEVEL; CORTICOSTERONE BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; ENERGY EXPENDITURE; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INHIBITION; EXTRACELLULAR MATRIX; FAT CONTENT; FATTY ACID OXIDATION; FOOD INTAKE; GALLSTONE; GENE DELETION; GENE EXPRESSION; GLUCAGON BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; GLUCOSE TOLERANCE TEST; GLYCEMIC CONTROL; GLYCOGEN ANALYSIS; GLYCOGEN SYNTHESIS; HISTOPATHOLOGY; HUMAN; IN SITU HYBRIDIZATION; IN VITRO STUDY; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SENSITIVITY; LIPID METABOLISM; LIPID OXIDATION; LIVER CARCINOGENESIS; LIVER CELL; METABOLIC DISORDER; METABOLIC RATE; METABOLIC REGULATION; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXYGEN CONSUMPTION; PHOSPHORYLATION; PLASMA HALF LIFE; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN METABOLISM; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION; WEIGHT REDUCTION;

ANIMALS; BILE ACIDS AND SALTS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRUG DELIVERY SYSTEMS; DRUG DESIGN; FIBROBLAST GROWTH FACTORS; GLUCOSE; HUMANS; METABOLIC SYNDROME X; PROTEIN ENGINEERING; RECEPTORS, FIBROBLAST GROWTH FACTOR;

EID: 80054696665     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2011.624514     Document Type: Review

References (49)

1. Zimmet P. Globalization, coca-colonization and the chronic disease epidemic: can the Doomsday scenario be averted? J Intern Med 2000;15:301-10 (Pubitemid 30180030)
2. Alves RC, Alves D, Guz B, et al. Advanced hepatocellular carcinoma. Review of targeted molecular drugs. Ann Hepatol 2011;10:21-7
3. Whittaker S, Marais R, Zhu AX. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 2010;29:4989-5005
4. Jones S. Mini-review: endocrine actions of fibroblast growth factor 19 Mol Pharm. 2008;5:42-8 (Pubitemid 351300033)
5. Fukumoto S. Actions and mode of actions of FGF19 subfamily members. Endocr J 2008;55:23-31 (Pubitemid 351520176)
6. Kharitonenkov A. FGFs and metabolism. Curr Opin Pharmacol 2009;9:805-10
7. Wu X, Li Y. Understanding the structure-function relationship between FGF19 and its mitogenic and metabolic activities. In: Kuro-o M, editor. Endocrine FGFs and Klothos. Landes Bioscience; Austin: 2011
8. Goetz R, Beenken A, Ibrahimi OA, et al. Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol Cell Biol 2007;27:3417-28 (Pubitemid 46685217)
9. Kurosu H, Kuro-O M. The Klotho gene family as a regulator of endocrine fibroblast growth factors. Mol Cell Endocrinol 2009;299:72-8
10. Long YC, Kharitonenkov A. Hormone-like fibroblast growth factors and metabolic regulation. Biochim Biophys Acta 2011;1812:791-5
11. Fu L, John LM, Adams SH, et al. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 2004;145:2594-603 (Pubitemid 38686202)
12. Wu X, Ge H, Lemon B, et al. Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob mice. Proc Natl Acad Sci USA 2009;106:14379-84
13. Wu X, Ge H, Lemon B, et al. Separating mitogenic and metabolic activities of fibroblast growth factor 19 (FGF19). Proc Natl Acad Sci USA 2010;107:14158-63
14. Tomlinson E, Fu L, John L, et al. Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 2002;143:1741-7 (Pubitemid 34415889)
15. Abu-Elheiga L, Matzuk MM, Abo-Hashema KA, Wakil SJ. Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2. Science 2001;291:2613-16 (Pubitemid 32249687)
16. Potthoff MJ, Boney-Montoya J, Choi M, et al. FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1alpha pathway. Cell Metab 2011;13:729-38
17. Kir S, Beddow SA, Samuel VT, et al. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science 2011;331:1621-4
18. Kim-Muller JY, Accili D. Cell biology. Selective insulin sensitizers. Science 2011;331:1529-31
19. Lee FY, Lee H, Hubbert ML, et al. FXR, a multipurpose nuclear receptor. Trends Biochem Sci 2006;31:572-80 (Pubitemid 44436939)
20. Mencarelli A, Fiorucci S. FXR an emerging therapeutic target for the treatment of atherosclerosis. J Cell Mol Med 2010;14:79-92
21. Inagaki T, Choi M, Moschetta A, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2005;2:217-25
22. Holt JA, Luo G, Billin AN, et al. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev 2003;17:1581-91 (Pubitemid 36828786)
23. Choi M, Moschetta A, Bookout AL, et al. Identification of a hormonal basis for gallbladder filling. Nat Med 2006;12:1253-5 (Pubitemid 44706926)
24. Smelt AH. Triglycerides and gallstone formation. Clin Chim Acta 2010;411:1625-31
25. Nicholes K, Guillet S, Tomlinson E, et al. A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am J Pathol 2002;160:2295-307 (Pubitemid 34663420)
26. Wu X, Ge H, Lemon B, et al. FGF19-induced hepatocyte proliferation is mediated through FGFR4 activation. J Biol Chem 2010;285:5165-70
27. Sawey ET, Chanrion M, Cai C, et al. Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by oncogenomic screening. Cancer Cell 2011;19:347-58
28. Desnoyers LR, Pai R, Ferrando RE, et al. Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene 2008;27:85-97
29. Pai R, Dunlap D, Qing J, et al. Inhibition of fibroblast growth factor 19 reduces tumor growth by modulating beta-catenin signaling. Cancer Res 2008;68:5086-95
30. Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 2009;8:235-53
31. Ogawa Y, Kurosu H, Yamamoto M, et al. betaKlotho is required for metabolic activity of fibroblast growth factor 21. Proc Natl Acad Sci USA 2007;104:7432-7 (Pubitemid 47185923)
32. Urakawa I, Yamazaki Y, Shimada T, et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006;444:770-4 (Pubitemid 44949607)
33. Kurosu H, Ogawa Y, Miyoshi M, et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 2006;281:6120-3 (Pubitemid 43847540)
34. Kurosu H, Choi M, Ogawa Y, et al. Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem 2007;282:26687-95 (Pubitemid 47501965)
35. Lin BC, Wang M, Blackmore C, Desnoyers LR. Liver-specific activities of FGF19 require Klotho beta. J Biol Chem 2007;282:27277-84 (Pubitemid 47501977)
36. Wu X, Ge H, Gupte J, et al. Co-receptor requirements for fibroblast growth factor-19 signaling. J Biol Chem 2007;282:29069-72 (Pubitemid 350043330)
37. Suzuki M, Uehara Y, Motomura-Matsuzaka K, et al. betaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c. Mol Endocrinol 2008;22:1006-14 (Pubitemid 351482834)
38. Ho HK, Pok S, Streit S, et al. Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention. J Hepatol 2009;50:118-27
39. Roidl A, Berger HJ, Kumar S, et al. Resistance to chemotherapy is associated with fibroblast growth factor receptor 4 up-regulation. Clin Cancer Res 2009;15:2058-66
40. Xu J, Lloyd DJ, Hale C, et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 2009;58:250-9
41. Kharitonenkov A, Shiyanova TL, Koester A, et al. FGF-21 as a novel metabolic regulator. J Clin Invest 2005;115:1627-35 (Pubitemid 40814671)
42. Wu X, Lemon B, Li X, et al. C-terminal tail of FGF19 determines its specificity toward Klotho co-receptors. J Biol Chem 2008;283:33304-9
43. Huang X, Yang C, Jin C, et al. Resident hepatocyte fibroblast growth factor receptor 4 limits hepatocarcinogenesis. Mol Carcinog 2009;48:553-62
44. Kharitonenkov A, Dunbar JD, Bina HA, et al. FGF-21/FGF-21 receptor interaction and activation is determined by betaKlotho. J Cell Physiol 2008;215:1-7 (Pubitemid 351363185)
45. Hu Z, Evarts RP, Fujio K, et al. Expression of fibroblast growth factor receptors flg and bek during hepatic ontogenesis and regeneration in the rat. Cell Growth Differ 1995;6:1019-25
46. Abuharbeid S, Czubayko F, Aigner A. The fibroblast growth factor-binding protein FGF-BP. Int J Biochem Cell Biol 2006;38:1463-8 (Pubitemid 43729304)
47. Harmer NJ, Pellegrini L, Chirgadze D, et al. The crystal structure of fibroblast growth factor (FGF) 19 reveals novel features of the FGF family and offers a structural basis for its unusual receptor affinity. Biochemistry 2004;43:629-40 (Pubitemid 38114050)
48. Mohammadi M, Olsen SK, Ibrahimi OA. Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev 2005;16:107-37 (Pubitemid 40616111)
49. Wu AL, Coulter S, Liddle C, et al. FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways. PLoS One 2011;6:e17868